title: Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.
abstract: Monoclonal antibodies (mAbs) have inaugurated the concepts of tumor-targeted therapy and personalized medicine. A new family of mAbs is currently emerging in the clinic, which target immune cells rather than cancer cells. These immune-targeted therapies have recently demonstrated long-term tumor responses in adults with refractory/relapsing metastatic solid tumors. Pediatric cancers are different from their adult counterparts in terms of histological features and immune infiltrates. However, the same immune checkpoint targets can be expressed within the microenvironment of pediatric tumors. The benefits of immune checkpoint blockade in pediatric cancers are currently under evaluation in early phase clinical trials.
authors: Institut d' Hématologie et d'Oncologie Pédiatrique, Centre de Lutte contre le Cancer Léon Bérard, Lyon, France.|Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
authors: Aurélien
authors: A
authors: Marabelle
authors: Antibody and Vaccine Group, Cancer Research UK Experimental Cancer Medicine Centre, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
authors: Juliet
authors: J
authors: Gray
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
keywords: anti-CTLA-4; anti-PD-1; anti-PD-L1; immune checkpoint blockade; monoclonal antibodies; pediatric cancers